INTRODUCTION
============

*Stenotrophomonas maltophilia*, commonly associated with respiratory infections in children and adults, is an emerging Gram-negative MDRO (multi-drug-resistant organism) of global significance ([@B5]). Currently, the incidence of *S. maltophilia* nosocomial infection is increasing, particularly for the immunocompromised (cancer, cystic fibrosis, drug addicts, and AIDS patients), dialysis patients, recipients of organ transplants, in addition to the reported cases of community-acquired *S. maltophilia*. The low outer membrane permeability of *S. maltophilia* renders it inherently resistant to most antibiotics, whilst the production of group 2e β-lactamase (L2) and group 3c β-lactamase (L1) confers resistance to β-lactam containing antibiotics ([@B2]). The *bla*~L1~ existed on a 200-kb plasmid, encoding a broad-spectrum metallo-β-lactamase which hydrolyses carbapenems ([@B23]; [@B4]), is usually produced at higher levels (induced) that hydrolyzes almost all known penicillins, cephalosporins, and carbapenems during β-lactam challenge. The ease of acquisition and spread of this antibiotic resistant gene of *bla*~L1~ in *S. maltophilia* emphasizes the need for antibiotic susceptibility testing of clinical isolates. At present, *bla*~L1~ has been identified in some clinical isolates of *S. maltophilia* with important drug resistance against carbapenems ([@B4]), so detection of *bla*~L1~ plays an important role to indicate the infection of *S. maltophilia* in the clinical work ([@B3]; [@B1]; [@B9]).

Recently, a number of molecular biology techniques have been used to detect different strains of *S. maltophilia* ([@B15]). PCR amplification of the 16S rRNA gene was used to detect *S. maltophilia* in blood samples of patients who are undergoing chemotherapy for acute leukemia or myelodysplastic syndrome ([@B15]). However, PCR requires specialized high-cost instruments and consumables. In addition, *Taq* DNA polymerase in PCR assays can be inactivated by inhibitors present in crude biological samples but the large fragment of *Bst* DNA polymerase (the large fragment of *Bst* DNA polymerase is part of *Bacillus stearothermophilus* DNA polymerase, it has 5′\>--3′\> DNA polymerase activity) in loop-mediated isothermal amplification (LAMP) assays is more resistant to inhibitors present in crude biological samples ([@B7]; [@B13]). Thus, another rapid, simple and cost effective assay is needed to complement current PCR methods. The LAMP method which was developed in 2000 relies on auto-cycling strand displacement DNA synthesis which proceeds under isothermal conditions, typically within 60 min, and in the presence of *Bst* DNA polymerase ([@B16]; [@B21]). In this study, we develop this new method to detect the *bla*~L1~ of *S. maltophilia.* The LAMP method has been shown to amplify target DNA with high-specificity, and it is used widely in the clinical detection of bacteria ([@B10]; [@B17]), viruses ([@B18]), parasites ([@B6]; [@B14]), and for fetal sex identification ([@B11]).

Data on the prevalence of *bla*~L1~ in *S. maltophilia* from ICU of Chinese hospitals are lacking. The objective of the current study is to develop a rapid, simple assay for *S. maltophilia* and to further investigate the infection status and the species distribution of *bla*~L1~ in clinic. At first, we designed five primer sets which each set targets six or eight sequences on the *bla*~L1~. The specificity and sensitivity of the primers for *bla*~L1~ was confirmed, and the LAMP method used for the detection of *bla*~L1~ in clinical samples. Then, basing on this LAMP assays, dissemination and molecular characterization of L1-producing *S. maltophilia* isolates was investigated at ICU patients in three top hospitals (the hospitals that have large scale and many patients) in Beijing, China.

MATERIALS AND METHODS {#s1}
=====================

BACTERIAL ISOLATES, IDENTIFICATION, MLST TYPING, AND ANTIMICROBIAL SUSCEPTIBILITY TESTING
-----------------------------------------------------------------------------------------

A total of 37 bacterial strains were used in this study to develop the LAMP assays, and their sources are listed in **Table [1](#T1){ref-type="table"}**. *S. maltophilia* K279a carrying *bla*~L1~ and *bla*~L2~ with the typical antimicrobial resistance properties was used as the positive control. The other species including common clinical infectious species and homologous species with *S. maltophilia* stored at our laboratory were used for estimating the sensitivity and specificity of the LAMP assay. 105 clinical nasopharyngeal swabs and sputum samples were collected from ICU hospitalized patients with clinically suspected multi-resistant infections in the 307 hospital, 302 hospital, and 301 hospital in China, and species identification was carried out using an automated system (Phoenix and BD systems) and matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS). 16S rDNA and *bla*~L1~ were validated by PCR-based sequencing, and their sequence showed 100% (for 16S rDNA) and 98--100% (for *bla*~L1~) identity with the sequences of previously reported genes, respectively. The allele number for each gene was assigned on the basis of the information in the MLST database ^[1](#fn01){ref-type="fn"}^. A combination of the allelic sequences of the seven genes yielded the allelic profile. Antimicrobial susceptibility testing was performed by microbroth dilution according to the Clinical and Laboratory Standards Institute (CLSI, Clinical and Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing; Twentieth informational supplement CLSI Document M100-S20, Wayne, PA, USA 2010.), and Etest strips (bioMérieux) for carbapenems. The carbapenemase activity of isolates was assessed by Etest MBLs.

###### 

Bacterial strains used in the current study.

  Species                                            Source
  -------------------------------------------------- --------------------------
  *Stenotrophomonas maltophilia-*2                   Clinical isolate
  *S. maltophilia-*17                                Clinical isolate
  *S. maltophilia*-24                                Clinical isolate
  *S. maltophilia*-25                                Clinical isolate
  *S. maltophilia*-36                                Clinical isolate
  *S. maltophilia*-41                                Clinical isolate
  *S. maltophilia*-51                                Clinical isolate
  *S. maltophilia*-58                                Clinical isolate
  *S. maltophilia*-63                                Clinical isolate
  *S. maltophilia*-65                                Clinical isolate
  *S. maltophilia*-66                                Clinical isolate
  *S. maltophilia*-67                                Clinical isolate
  *S. maltophilia -*3859                             Clinical isolate
  *S. maltophilia-*4621                              Clinical isolate
  *S. maltophilia-*WJ2                               Clinical isolate
  *S. maltophilia-*K279a                             Our microorganism center
  *Acinetobacter baumannii* B260                     Our microorganism center
  *A. baumannii* H18                                 Our microorganism center
  *Bacillus megatherium* 4623                        Our microorganism center
  Beta hemolytic *Streptococcus* group A CMCC32213   Our microorganism center
  *Bordetella pertussis* ATCC 18530                  Our microorganism center
  *Brucella suis* 3572                               Clinical isolate
  *Corynebacterium diphtheriae* CMCC38001            Our microorganism center
  Enterotoxigenic *Escherichia coli* 44824           Our microorganism center
  *Mycobacterium tuberculosis* 8362                  Our microorganism center
  *Neisseria meningitidis* group B CMCC29022         Our microorganism center
  *Salmonella aberdeen* 9264                         Our microorganism center
  *Salmonella enteritidis* 50326-1                   Our microorganism center
  *Salmonella paratyphi* 86423                       Our microorganism center
  *Shigella flexneri* 4536                           Our microorganism center
  *Shigella sonnei* 2531                             Our microorganism center
  *Staphylococcus aureus* 2740                       Our microorganism center
  *Vibrio carchariae* 5732                           Our microorganism center
  *V. cholera* 3802                                  Our microorganism center
  *V. parahaemolyticus* 5474                         Our microorganism center
  *Yersinia enterocolitica* 1836                     Our microorganism center
  *Y. pestis* 2638                                   Our microorganism center

The strains were screened for the presence of known MBL genes (*bla*~V\ IM~, *bla*~IMP~, *bla*~SPM-1~, *bla*~GIM-1~, *bla*~SIM-1~, *bla*~AIM-1~, and *bla*~NDM-1~) by PCR with primers as reported previously ([@B19]). The strains were also screened for the presence of other β-lactamase genes (*bla*~CTX~, *bla*~CMY~, etc.; [@B20]).

ISOLATION OF GENOMIC DNA
------------------------

The 37 bacterial strains and the 105 clinical samples were cultured in brain heart infusion (BHI) broth at 37°C according to a standard protocol. Chelex^®^ 100 was used to extract total genomic DNA (including plasmid DNA) from 5 ml overnight bacterial cultures. Briefly, 500 μl bacterial suspension was centrifuged at 10,000 × *g* for 2 min and the supernatant discarded. The pellet was resuspended in 500 μl distilled water and 500 μl Chelex DNA extraction buffer (25 mM NaOH, 10 mM Tris-HCl, 1% Triton X-100, 1% NP-40, 0.1 mM EDTA, 2% Chelex-100) added. The cell suspension was heated in boiling water for 10 min, held on ice for 5 min, and centrifuged at 14,000 × *g* for 2 min. The extracted DNA was used as template in the LAMP and PCR reactions.

As for isolation of DNA from clinical sputum samples, DNA was extracted directly from 200 μl clinical sputum samples with the TIANamp Genomic DNA Kit (TIANGEN Biotech Co., Ltd., Beijing, China). The DNA was purified with the SV GEL and PCR Clean-Up System (Promega Co., USA). The DNA concentration was detected using the Spectrophotometer ND-1000 (Thermo Fisher Scientific, Inc., USA).

PRIMER DESIGN
-------------

A total of 20 *bla*~L1~ in the NCBI GenBank database (GenBank: HQ822273.1; EF126060.1; EF126061.1; AM743169.1; AB294542.1; AJ251814.1; JF705927.1; JF705926.1; EF126051.1; EF126054.1; EF126053.1; EF601224.1; AB294547.1; AB294545.1; AJ291672.1; AF010282.1; AB194306.1; AJ289085.1; AJ289086.1; AB194305.1) were compared, then the sequences of conserved regions were chosen to design the primer sets. Primer Explorer V4 software ^[2](#fn02){ref-type="fn"}^ was used to design the outer forward primer (F3), outer backward primer (B3), forward inner primer (FIP), backward inner primer (BIP) and backward loop primer (loop B), used to accelerate the amplification reaction. Mergers of bases are used to circumvent the mutational site (**Table [2](#T2){ref-type="table"}**). The FIP and BIP primers were linked by a four thymidine spacer (TTTT). Conventional PCR was performed using primers labeled L1-23-F3 and L1-23-B3. The primers were synthesized by Sangon Biotech Co., Ltd. (Shanghai, China).

###### 

Primers used for the amplification of *bla*~**L1**~.

  Primer     Type             Sequence (5'--3')
  ---------- ---------------- ----------------------------------------------------------
  L1-23F3    Forward outer    CGGCATGCCACAGATGG
  L1-23B3    Backward outer   GCAGCACCGCCGTTTCT
  L1-23FIP   Forward inner    TCAATCGCAGGTCCTGCGGTTTTCGGTCACCTGCTGGACAAC
  L1-23BIP   Backward inner   CTY(C/T)AGCCATGCGCAY(T/C)GCS(C/G)GATTTTGCATTGGCCGCCACATG
  L1-23LB    Loop backward    TCGCCGAGCTCAAGCGT

LAMP REACTION
-------------

A 25 μl reaction volume was used for all LAMP reactions and contained the following components (final concentration): 20 mM Tris-HCl (pH 8.8), 10 mM KCl, 10 mM (NH~4~)~2~SO~4~, 0.1% Tween 20, 0.8 M betaine, 8 mM MgSO~4~, 1.4 mM each dNTP, and 8 U *Bst* DNA polymerase. The amount of primer per reaction was 40 pmol FIP and BIP, 20 pmol LB, 5 pmol F3 and B3. The appropriate amount of DNA template was included in the reaction volume. The LAMP assay proceeded in a reaction tube (Eiken Chemical Co., Ltd., Tochigi, Japan) for 60 min at 65°C.

DETECTION OF LAMP PRODUCTS
--------------------------

Two independent methods, based on either sample turbidity or fluorescence were used to detect LAMP products. Real-time changes in turbidity were monitored by measuring the optical density (λ~650~ ~nm~) at 6 s intervals, for each LAMP reaction in a Loopamp real-time turbidimeter (LA-320c; Eiken Chemical Co., Ltd.). The changes in turbidity arose from the presence of the amplification by-product Mg~2~P~2~O~7~ (a white precipitate).

The second method used direct visual inspection to assess color changes in the presence of the fluorescent metal ion indicator calcein/Mn^2+^ complex. One microliter of calcein/Mn^2+^ complex (Eiken Chemical Co., Ltd.) was added to 25μl LAMP reaction volume prior to the commencement of the LAMP assay. On completion of the reaction a change in color from orange to green indicated a positive reaction, whilst no color change indicated a negative reaction. The color change was observed by the naked eye under natural light or under UV light at 365 nm.

PCR DETECTION
-------------

A 25 μl reaction volume was used for all PCR reactions and contained the following components: 12.5 μl PCR Taq MasterMix (Tiangen Biotech Co., Ltd.), 9.5 μl double distilled water, 1 μM L1-23F3 and L1-23B3 primers, and DNA template. The oligonucleotide primers used for cloning *bla*~L1~ are F: 5′\>-atgcgttctaccctgctcgccttcgcc-3′\> and R: 5′\>-tcagcgggccccggccgtttccttggccag-3′\>. The PCR was carried out as follows: initial PCR activation step, 94°C for 2 min; amplification, 35 cycles of 94°C for 30 s, 59°C for 30 s, and 72°C for 30 s; final extension step, 72°C for 10 min. The amplicons were purified using a PCR Purification Kit (TIANGEN Biotech Co., Ltd., Beijing, China) and sequenced by Beijing AuGCT DNASYN Biotechnology Co., Ltd. The sequences were compared with sequences in the GenBank database.

RESULTS
=======

THE OPTIMAL PRIMER SETS FOR LAMP ASSAY
--------------------------------------

Five primer sets were detected in the same reaction condition using real-time turbidimeter and their turbidity curves were draw at 650 nm according to the amplified results. The optimal primer sets amplified the target sequence with the shortest time among them was chosen for further investigation (see **Table [2](#T2){ref-type="table"}**).

SENSITIVITY OF THE LAMP METHOD FOR *bla*~L1~ DETECTION
------------------------------------------------------

The sensitivity of the LAMP method for detecting *bla*~L1~ was evaluated using genomic DNA extracted from *S. maltophilia* K279a (Wizard Genomic DNA purification Kit), serially diluted 10-fold from 379 ng/μl to 0.00379 pg/μl. As shown in **Figure [2A](#F2){ref-type="fig"}**, the detection limit of the LAMP assay for *bla*~L1~ was 3.790 pg/μl. Visual inspection of the color change, post-LAMP assay, and in the presence of calcein/Mn^2+^ complex confirmed reactions positive (green) and negative (orange) for *bla*~L1~(**Figure [2B](#F2){ref-type="fig"}**). The results from the two detection methods were in agreement with sensitivity for *bla*~L1~. PCR reactions on the serially diluted DNA using primers L1-23F3 and L1-23B3 were also conducted, and the detection limit for *bla*~L1~ was established as 379 pg/μl (**Figure [2C](#F2){ref-type="fig"}**).

SPECIFICITY OF THE LAMP METHOD FOR *bla*~L1~ DETECTION
------------------------------------------------------

The specificity of the LAMP method for detecting *bla*~L1~ was evaluated using *S. maltophilia* K279a with *bla*~L1~ as the positive control, distilled water as the negative control, and 21 strains without carrying *bla*~L1~ including common clinical infectious species and homologous species with *S. maltophilia* as test subjects. As shown in **Figure [1A](#F1){ref-type="fig"}**, turbidity increased only when *S. maltophilia* K279a with *bla*~L1~ was used as template DNA in the LAMP assay. When distilled water and the 21 remaining bacterial species were used as template, no changes in turbidity were recorded. These results suggest that the primers had good specificity for *bla*~L1~. In addition, these results are consistent with those obtained using the fluorescent indicator calcein/Mn^2+^ complex. Whereby, only the LAMP assay with *S. maltophilia* K279a with *bla*~L1~ recorded a color change from orange to green, indicative of a positive reaction (**Figure [1B](#F1){ref-type="fig"}**). Whilst, all test samples negative for *bla*~L1~ and the negative control remained orange, indicative of a negative reaction.

![**Specificity of the LAMP method for *bla*~**L1**~ gene detection.** It has two parts, **(A)** is the graphic and **(B)** is the photography of microtubes. The reaction proceeded at 65°C for 65 min. Turbidity was monitored in the Loopamp real-time turbidimeter and the OD~(λ650nm)~ recorded at 6 s intervals. L1, *Brucella suis* 3572; L2, *Bacillus megatherium* 4623; L3, *Vibrio carchariae* 5732; L4, *Acinetobacter baumannii* B260; L5, *Corynebacterium diphtheriae* CMCC38001; L6, *Acinetobacter baumannii* H18; L7, *Mycobacterium tuberculosis* 8362; L8, *Shigella sonnei* 2531; L9, *Shigella flexneri* 4536; L10, *Salmonella enteritidis* 50326-1; L11, *Yersinia enterocolitica* 1836; L12, *Vibrio parahaemolyticus* 5474; L13, *Salmonella paratyphi* 86423; L14, *Neisseria meningitidis group B* CMCC29022; L15, Enterotoxigenic *E. coli* 44824; L16, Beta hemolytic *Streptococcus group A* CMCC32213; L17, *Yersinia pestis* 2638; L18, *Salmonella aberdeen* 9264; L19, *Vibrio cholera* 3802; L20, *Staphylococcus aureus* 2740; L21, *Bordetella pertussis* ATCC 18530*;* L22, positive control (*S. maltophilia -*K279a); L23, negative control (distilled water).](fmicb-05-00692-g001){#F1}

![**Comparison of the sensitivities for *bla*~**L1**~ gene detection by LAMP and conventional PCR methods.** Pure genomic DNA extracted from *S. maltophilia-*K279a was diluted tenfold (379.0 ng/μl to 0.00379 pg/μl) and the DNA assayed by LAMP **(A,B)** and PCR **(C)**. **(A)** Turbidity was monitored using the Loopamp real-time turbidimeter and the OD recorded at 650 nm, at 6 s intervals. **(B)** Visual inspection of the color change, post-LAMP assay, and in the presence of calcein/Mn^2+^ complex. **(C)** PCR products were analyzed by 2% agarose gel electrophoresis and stained with ethidium bromide. The DNA marker is D2000 DNA Marker (Tiangen Biotech Co., Ltd.) The size is about 179 bp.](fmicb-05-00692-g002){#F2}

DISSEMINATION OF L1-PRODUCING *S. maltophilia* IN CLINICAL
----------------------------------------------------------

A total of 105 clinical sputum samples and nasopharyngeal swabs were collected for LAMP-based surveillance of *bla*~L1~ from 105 ICU patients with clinically suspected multi-resistant infections from the department of Respiratory Diseases in three top hospitals. Ten pairs of sputum samples and nasopharyngeal swabs from healthy people were collected as controls.

All clinical samples were analyzed by LAMP and PCR simultaneously. Of the 105 patients samples, 22 were confirmed to be infected with *S. maltophilia* with *bla*~L1~ and 83 negative samples by the LAMP assay (**Figure [3](#F3){ref-type="fig"}**), whilst the PCR assay detected 13 positive samples, and 92 negative samples. Then 22 strains of *S. maltophilia* were isolated and identified from all of clinical sputum samples and swabs samples, which the positive samples were in accordence with those in LAMP assay. *S. maltophilia* with *bla*~L1~ was positively identified 100% by LAMP and 86.7% by PCR, respectively. None of the samples from healthy people was tested as positive for *bla*~L1~. Thus, the results showed the LAMP assays is more sensitive and the specific than PCR for diagnosis of *S. maltophilia* in clinical practice.

![**Loop-mediated isothermal amplification results for 15 *S. maltophilia* strains positive for *bla*~**L1**~ isolated from 15 clinical samples. (A)** Turbidity was monitored using Loopamp, and the OD measured at 650 nm every 6 s. **(B)** Visual inspection of calcein/Mn^2+^ complex associated color changes post-LAMP assay. 1, *S. maltophilia*-2; 2, *S. maltophilia*-17; 3, *S. maltophilia*-24; 4, *S. maltophilia*-25; 5, *S. maltophilia*-36; 6, *S. maltophilia*-41; 7, *S. maltophilia*-51; 8, *S. maltophilia*-58; 9, *S. maltophilia*-63; 10, *S. maltophilia*-65; 11, *S. maltophilia*-66; 12, *S. maltophilia*-67; 13, *S. maltophilia*-3859; 14, *S. maltophilia*-4621; 15, *S. maltophilia* -WJ2; 16, positive control (*S. maltophilia-*K279a); 17, negative control (distilled water).](fmicb-05-00692-g003){#F3}

The sequence analysis of the *bla*~L1~ genes from *S. maltophilia* isolates confirmed conservation with the nucleotide sequences of reported genes or with only a few sites mutated. In the MLST analysis of *S. maltophilia*, the results of seven housekeeper genes recovered that 22 strains belonged to different sequence type (ST) including ST4, ST8, ST 25, ST 28, ST29, or ST31, respectively. To further characterize the 22 strains carrying *bla*~L1~ genes, the susceptibility pattern was detected and clearly showed that all isolates had highly resistant to β-lactam antibiotics. The isolates also tested positive for MBLs in both the imipenem-EDTA double-disk synergy test (DDST) and modified Hodge test (MHT).

Furthermore, PCR screening of the isolates were performed for the known MBL genes including *bla*~NDM-1~, *bla*~V\ IM~, *bla*~IMP~, *bla*~SPM-1~, *bla*~GIM-1~, *bla*~SIM-1~, *bla*~AIM-1~, and *bla*~L2~ ([@B19]). PCR yielded products of 22 isolates with expected sizes for *bla*~L1~, and sequencing of these genes showed 100% identities with previously reported genes. It's interesting to note that the isolate named as *S. maltophilia* DCPS-01 contained L1 and L2 β-lactamase genes with a novel *bla*~NDM-1~ which has attracted wide attention because of its superior resistance to all β-lactam antibiotics, which presented increased carbapenemase activity to all β-lactams (MIC \>128 μg/mL for imipenem and meropenem), aminoglycosides and quinolones, and was only susceptible to tigecycline and colistin.

Therefore, our data showed the diversity genotypic features of *S. maltophilia* carrying *bla*~L1~ indicated wide spread in the respiratory infections. Importantly, the emergence of these powerful co-occurring resistance mechanisms described here provides warning that future therapeutic options may be seriously limited.

DISCUSSION
==========

*Stenotrophomonas maltophilia* is a widespread environmental bacterium that has become a nosocomial pathogen of increasing importance. It is currently the third most common nosocomial non-fermenting bacteria, behind *Pseudomonas aeruginosa* and *Acinetobacter baumannii*, and is associxated with crude mortality rates ranging from 14 to 69% in patients with bacteraemias ([@B12]; [@B22]). Of the 1661 antibiotic resistant strains of *S. maltophilia* recovered from 14 hospitals across several regions of China during 2010, the majority (97.5%) were isolated from patients. Approximately 68.3% of strains were isolated from patients ≥60 years of age, whilst only 4.8% were from patients \<18 years of age. Most (83.0%) isolates were recovered from sputum and respiratory tract secretions (The data and information from CHINET: CHINET 2010 surveillance of antibiotic resistance in *S. maltophilia* in China). Within hospitals, the bacterium is most often found in water sources, and can be a contaminant of hospital equipment such as nebulizers and intravenous catheters. From these sources, the organism can infect patients, resulting in a wide spectrum of symptoms dependent upon the site of infection, though, most commonly, *S. maltophilia* causes bacteraemias or respiratory tract infections ([@B8]). β-Lactam resistance is due to the expression of the β-lactamases L1, which together hydrolyze the full range of β-lactam drugs, with the exception of monobactams ([@B23]). It is therefore necessary to detect and monitor antibiotic resistance, persistence and spread of *S. maltophilia* within the community and in health care settings.

Loop-mediated isothermal amplification assays are generally less time and labor intensive compared with traditional methods of pathogen detection, in part because the amplification of the target gene is performed at a constant temperature, and the reaction times are usually less than an hour. To date, a method for detecting *S. maltophilia* based on LAMP assays has not been reported. In the current study, we designed primers specific for the metallo-β-lactamase *bla*~L1~ for use in a LAMP assay to detect *S. maltophilia* in clinical samples. Results from the specificity and sensitivity analyses demonstrated that the LAMP method detected genomic DNA at 3.79 pg/μl, and was specific for the β-lactamase *bla*~L1~. In the specificity and sensitivity detection, we only use the *bla*~L1~ of *S. maltophilia* K279a as the target gene, although many other *S. maltophilia* strains do not have the same sequence of *bla*~L1~, the most conserve regions of *bla*~L1~ were chosed to design the decisive primers. In LAMP reaction, it is not true that all the primers should combine with the target sequence. The decisive primers are the FIP and BIP, if the FIP and BIP can combine with the target sequence, the reaction is certain to occur, well, of course, more novel experiments should be made to ensure this conclusion. Although the LAMP method has complex amplification principle, the assay is rapid, easy to operate, highly sensitive and specific, and proceeds under isothermal conditions. We believe this assay would be suitable for use in inspection and quarantine departments and in health care units to test for *S. maltophilia*, and we anticipate its routine use in hospital testing regimes, particularly for rapid clinical testing.

A drawback of the LAMP method is the relatively high false-positive rates; a consequence of the assay's high sensitivity ([@B16]). Strict spatial separation of reagent preparation from the testing area is necessary to avoid contamination. In the current study, a sealing agent was applied to the reaction tube once the reaction mixture had been prepared, and its presence is useful in preventing contamination.

In conclusion, we designed a detection method based on LAMP for the specific, sensitive, rapid, and effective detection of the metallo-β-lactamase *bla*~L1~ of *S. maltophilia.* We believe this technique would greatly benefit hospitals and health units, and we anticipate that LAMP will become the gold standard for the rapid detection of pathogens in clinical samples. At the same time, this report provides new insights into the mechanisms of drug resistance and warning that future therapeutic options may be seriously limited.
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